Novel Therapeutic Approaches To IBD: Considerations for Optimal Positioning in Clinical Practice

Novel Therapeutic Approaches To IBD: Considerations for Optimal Positioning in Clinical Practice

On-Demand Webcast
Chair

David T. Rubin, MD, FACG
University of Chicago Medicine
Chicago, Illinois

Faculty

Christina Y. Ha, MD
Cedars Sinai Medical Center
Los Angeles, California

Bruce E. Sands, MD, MS
Icahn School of Medicine at Mount Sinai
New York, New York

Target Audience

This educational activity is designed and certified for the entire IBD healthcare team and includes education for gastroenterologists, pediatric gastroenterologists, surgeons, physicians, PhDs, researchers, pharmacists, nurse practitioners, physician assistants, gastroenterology nurses, and residents/fellows/students.

Overview

The therapeutic landscape in inflammatory bowel disease (IBD) was transformed 20 years ago by the arrival of monoclonal antibodies targeting tumor necrosis factor alpha (TNFα), enabling a paradigm shift away from the traditional step-care approach to therapy focused primarily on symptom alleviation in favor of a more aggressive top-down approach more likely to induce and maintain remission and mucosal healing (MH). Despite considerable advances in the understanding of the optimal use of these agents, however, not all patients achieve their treatment goals on anti-TNFα therapy, and many patients who initially respond to therapy lose response over time.

Fortunately, new insights into the pathophysiology of IBD are significantly expanding the armamentarium in IBD beyond TNFα inhibitors. However, between- and within-class distinctions in the mechanism of action, efficacy, and safety of new and emerging targeted therapies and their evolving clinical data pool creates a knowledge gap with respect to informed therapeutic selection and sequencing for each individual patient. For optimal patient care, clinicians must have a thorough understanding of the clinical data and latest guideline recommendations surrounding a diverse array of new and emerging therapies in order to improve the care of patients with IBD.

Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Describe the current understanding of IBD pathophysiology with respect to inflammatory signaling pathways and potential therapeutic targets
  2. Evaluate the mechanisms of action and available efficacy and safety data surrounding new and emerging therapies for the treatment of IBD
  3. Integrate the latest clinical data into current and future personalized therapeutic strategies for the management of IBD

Release Date: February 14, 2020

Expiration Date: February 14, 2021

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Support

This activity has been supported through an independent educational grant from Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Accreditation

 The University of Cincinnati (UC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

University of Cincinnati designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 1.25 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours.

CPE

This knowledge-based activity (JA0006201-9999-20-087-H01-P) is approved for 1.25 contact hour (0.125 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises of David T. Rubin, Md, FACG; Chistina Y. Ha, MD; and Bruce E. Sands, MD, MS

Imedex planners and staff include Chris Bolwell and Kelly Jackson.

NACCME planners and staff include Mike Kearney, Mary Johnson, and Jennifer Ilcyn.

University of Cincinnati (UC) planners and staff include Barbara Forney, Bruce Gebhardt, MD, and Susan Tyler.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

David T. Rubin, MD, FACG reports being a Consultant for Abbvie Abgenomics Allergan, Inc. Biomica Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone Seres Therapeutics, Shire, Takeda, and Target PharmaSolutions, Inc.; Grant/Research Support for Abbvie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire and Takeda; as well as being American College of Gastroenterology - Board of Trustees Cornerstones Health, Inc. (non-profit), Co-Founder GoDuRn, LLC, Co-Founder (no financial support recvd)

Christina Y. Ha, MD reports being a Consultant/Advisory Board Member for AbbVie, Genetech, Janssen, Pfizer, Samsung Bioepis and Takeda; offering Grant support for Pfizer; and being on the Speakers Bureau for AbbVie and Medical Speakers Network

Bruce E. Sands, MD, MS reports being a Consultant for Ingelheim, Boston Pharmaceuticals, Capella Bioscience,Celltrion Healthcare, Genentech, Hoffmann-La Roche, AG Ironwood Pharmaceuticals, Janssen, Lilly, Morphic Therapeutic, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Laboratorie, Salix, Shire, Takeda Pharmaceuticals, TARGET PharmaSolutions, Theravance Biopharma, and Vivelix Pharmaceuticals; and offering Grant/Research Support for Theravance Biopharma

Chris Bolwell  is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.